KAILERA THERAPEUTICS INC (KLRA) — insider trading
Health Care · NASDAQ
KAILERA THERAPEUTICS INC (KLRA) has 48 reported SEC Form 4 insider transactions in our data, including 5 open-market purchases among the most recent 48 (latest 2026-09-07).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-07 | Nicholson Nur | Officer (Chief Technology Officer) | Grant / award / vesting (derivative) | 220,000 | — | $0 | Form 4 |
| 2026-07-06 | Tregoning Kathleen | Officer (See Remarks) | Grant / award / vesting (derivative) | 175,000 | — | $0 | Form 4 |
| 2026-06-09 | Renaud Ronald C JR | Director, Officer (CEO & President) | Option exercise / conversion (derivative) | 38,094 | — | $0 | Form 4 |
| 2026-06-09 | Renaud Ronald C JR | Director, Officer (CEO & President) | Option exercise / conversion | 38,094 | $5.25 | $200.0K | Form 4 |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | Conversion of derivative (derivative) | 708,814 | — | $0 | Form 4 |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | Conversion of derivative (derivative) | 4,968,789 | — | $0 | Form 4 |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | Conversion of derivative | 2,034,133 | — | — | Form 4 |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | Conversion of derivative | 9,477,719 | — | — | Form 4 |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | 10% owner | Conversion of derivative (derivative) | 2,026,820 | — | — | Form 4 |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | 10% owner | Conversion of derivative (derivative) | 8,250,000 | — | — | Form 4 |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | 10% owner | Open-market purchase | 500,000 | $16.00 | $8.00M | Form 4 |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK | 10% owner | Conversion of derivative | 10,276,820 | — | — | Form 4 |
| 2026-04-20 | Kaplan Andrew T. | Director, 10% owner | Conversion of derivative (derivative) | 17,857,143 | — | $0 | Form 4 |
| 2026-04-20 | Kaplan Andrew T. | Director, 10% owner | Open-market purchase | 8,398,438 | $16.00 | $134.38M | Form 4 |
| 2026-04-20 | Kaplan Andrew T. | Director, 10% owner | Conversion of derivative | 17,857,143 | — | — | Form 4 |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Fund IV, L.P.; BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P. | 10% owner | Conversion of derivative (derivative) | 4,145,768 | — | $0 | Form 4 |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Fund IV, L.P.; BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P. | 10% owner | Conversion of derivative (derivative) | 16,875,000 | — | $0 | Form 4 |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Fund IV, L.P.; BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P. | 10% owner | Open-market purchase | 1,562,500 | $16.00 | $25.00M | Form 4 |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Fund IV, L.P.; BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P. | 10% owner | Conversion of derivative | 4,145,768 | — | — | Form 4 |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Fund IV, L.P.; BCLS Fund IV Investments GP, LLC; BCLS Fund IV Investments, L.P. | 10% owner | Conversion of derivative | 16,875,000 | — | — | Form 4 |
| 2026-04-20 | Koppel Adam | Director, 10% owner | Conversion of derivative (derivative) | 4,145,768 | — | $0 | Form 4 |
| 2026-04-20 | Koppel Adam | Director, 10% owner | Conversion of derivative (derivative) | 16,875,000 | — | $0 | Form 4 |
| 2026-04-20 | Koppel Adam | Director, 10% owner | Open-market purchase | 1,562,500 | $16.00 | $25.00M | Form 4 |
| 2026-04-20 | Koppel Adam | Director, 10% owner | Conversion of derivative | 4,145,768 | — | — | Form 4 |
| 2026-04-20 | Koppel Adam | Director, 10% owner | Conversion of derivative | 16,875,000 | — | — | Form 4 |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC; Bain Capital XIV General Partner, LLC; Bain Capital Fund XIV, L.P.; BCPE Perseus Investor GP, LLC; BCPE Perseus Investor, LP | 10% owner | Conversion of derivative (derivative) | 17,857,143 | — | $0 | Form 4 |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC; Bain Capital XIV General Partner, LLC; Bain Capital Fund XIV, L.P.; BCPE Perseus Investor GP, LLC; BCPE Perseus Investor, LP | 10% owner | Open-market purchase | 8,398,438 | $16.00 | $134.38M | Form 4 |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC; Bain Capital XIV General Partner, LLC; Bain Capital Fund XIV, L.P.; BCPE Perseus Investor GP, LLC; BCPE Perseus Investor, LP | 10% owner | Conversion of derivative | 17,857,143 | — | — | Form 4 |
| 2026-04-16 | Pagan Douglas W. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-04-16 | Pagan Douglas W. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-04-16 | Clyburn Frank | Director | Grant / award / vesting (derivative) | 38,300 | — | $0 | Form 4 |
| 2026-04-16 | Hite Christopher | Director | Grant / award / vesting (derivative) | 38,300 | — | $0 | Form 4 |
| 2026-04-16 | Wasserman Scott M. | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-04-16 | Wasserman Scott M. | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-04-16 | MACKAY MARTIN | Director | Grant / award / vesting (derivative) | 38,300 | — | $0 | Form 4 |
| 2026-04-16 | Coleman Jamie Beth | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 75,000 | — | $0 | Form 4 |
| 2026-04-16 | Coleman Jamie Beth | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 75,000 | — | $0 | Form 4 |
| 2026-04-16 | MILLIGAN JOHN F | Director | Grant / award / vesting (derivative) | 38,300 | — | $0 | Form 4 |
| 2026-04-16 | Burgess Paul D. | Officer (See Remarks) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-04-16 | Burgess Paul D. | Officer (See Remarks) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-04-16 | Renaud Ronald C JR | Director, Officer (CEO & President) | Grant / award / vesting (derivative) | 300,000 | — | $0 | Form 4 |
| 2026-04-16 | Renaud Ronald C JR | Director, Officer (CEO & President) | Grant / award / vesting (derivative) | 300,000 | — | $0 | Form 4 |
| 2026-04-16 | Akamine Scott | Officer (Chief Legal Officer) | Grant / award / vesting (derivative) | 60,000 | — | $0 | Form 4 |
| 2026-04-16 | Akamine Scott | Officer (Chief Legal Officer) | Grant / award / vesting (derivative) | 60,000 | — | $0 | Form 4 |
| 2026-04-16 | Cloghessy Paula | Officer (Chief People Officer) | Grant / award / vesting (derivative) | 60,000 | — | $0 | Form 4 |
| 2026-04-16 | Cloghessy Paula | Officer (Chief People Officer) | Grant / award / vesting (derivative) | 60,000 | — | $0 | Form 4 |
| 2026-04-16 | Kaplan Andrew T. | Director, 10% owner | Grant / award / vesting (derivative) | 38,300 | — | $0 | Form 4 |
| 2026-04-16 | Koppel Adam | Director, 10% owner | Grant / award / vesting (derivative) | 38,300 | — | $0 | Form 4 |
Ask the chat about KLRA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: KAILERA THERAPEUTICS INC (KLRA).
Last updated 2026-09-07 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.